Human Clinical-Grade Parthenogenetic ESC-Derived Dopaminergic Neurons Recover Locomotive Defects of Nonhuman Primate Models of Parkinson's Disease
Summary: Clinical application of stem cell derivatives requires clinical-grade cells and sufficient preclinical proof of safety and efficacy, preferably in primates. We previously successfully established a clinical-grade human parthenogenetic embryonic stem cell (hPESC) line, but the suitability of...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-07-01
|
Series: | Stem Cell Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213671118302273 |
id |
doaj-f77f4dbd823b467fa8caeb5efda5c8ce |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yu-Kai Wang Wan-Wan Zhu Meng-Hua Wu Yi-Hui Wu Zheng-Xin Liu Ling-Min Liang Chao Sheng Jie Hao Liu Wang Wei Li Qi Zhou Bao-Yang Hu |
spellingShingle |
Yu-Kai Wang Wan-Wan Zhu Meng-Hua Wu Yi-Hui Wu Zheng-Xin Liu Ling-Min Liang Chao Sheng Jie Hao Liu Wang Wei Li Qi Zhou Bao-Yang Hu Human Clinical-Grade Parthenogenetic ESC-Derived Dopaminergic Neurons Recover Locomotive Defects of Nonhuman Primate Models of Parkinson's Disease Stem Cell Reports |
author_facet |
Yu-Kai Wang Wan-Wan Zhu Meng-Hua Wu Yi-Hui Wu Zheng-Xin Liu Ling-Min Liang Chao Sheng Jie Hao Liu Wang Wei Li Qi Zhou Bao-Yang Hu |
author_sort |
Yu-Kai Wang |
title |
Human Clinical-Grade Parthenogenetic ESC-Derived Dopaminergic Neurons Recover Locomotive Defects of Nonhuman Primate Models of Parkinson's Disease |
title_short |
Human Clinical-Grade Parthenogenetic ESC-Derived Dopaminergic Neurons Recover Locomotive Defects of Nonhuman Primate Models of Parkinson's Disease |
title_full |
Human Clinical-Grade Parthenogenetic ESC-Derived Dopaminergic Neurons Recover Locomotive Defects of Nonhuman Primate Models of Parkinson's Disease |
title_fullStr |
Human Clinical-Grade Parthenogenetic ESC-Derived Dopaminergic Neurons Recover Locomotive Defects of Nonhuman Primate Models of Parkinson's Disease |
title_full_unstemmed |
Human Clinical-Grade Parthenogenetic ESC-Derived Dopaminergic Neurons Recover Locomotive Defects of Nonhuman Primate Models of Parkinson's Disease |
title_sort |
human clinical-grade parthenogenetic esc-derived dopaminergic neurons recover locomotive defects of nonhuman primate models of parkinson's disease |
publisher |
Elsevier |
series |
Stem Cell Reports |
issn |
2213-6711 |
publishDate |
2018-07-01 |
description |
Summary: Clinical application of stem cell derivatives requires clinical-grade cells and sufficient preclinical proof of safety and efficacy, preferably in primates. We previously successfully established a clinical-grade human parthenogenetic embryonic stem cell (hPESC) line, but the suitability of its subtype-specific progenies for therapy is not clear. Here, we compared the function of clinical-grade hPESC-derived midbrain dopaminergic (DA) neurons in two canonical protocols in a primate Parkinson's disease (PD) model. We found that the grafts did not form tumors and produced variable but apparent behavioral improvement for at least 24 months in most monkeys in both groups. In addition, a slight DA increase in the striatum correlates with significant functional improvement. These results demonstrated that clinical-grade hPESCs can serve as a reliable source of cells for PD treatment. Our proof-of-concept findings provide preclinical data for China's first ESC-based phase I/IIa clinical study of PD (ClinicalTrials.gov number NCT03119636). : Human ESCs are a potential source of regenerative medicine. However, safety and efficacy of ESC derivatives must be validated strictly before clinical application. Wang et al. manufactured clinical-grade human parthenogenetic ESC-derived DA neurons under CGMP conditions. The authors found that transplantation of these DA cells into monkeys was safe and provided preclinical data for human ESC-based clinical trials. Keywords: embryonic stem cell, Parkinson's disease, cell therapy, dopaminergic neuron, nonhuman primate, monkey |
url |
http://www.sciencedirect.com/science/article/pii/S2213671118302273 |
work_keys_str_mv |
AT yukaiwang humanclinicalgradeparthenogeneticescderiveddopaminergicneuronsrecoverlocomotivedefectsofnonhumanprimatemodelsofparkinsonsdisease AT wanwanzhu humanclinicalgradeparthenogeneticescderiveddopaminergicneuronsrecoverlocomotivedefectsofnonhumanprimatemodelsofparkinsonsdisease AT menghuawu humanclinicalgradeparthenogeneticescderiveddopaminergicneuronsrecoverlocomotivedefectsofnonhumanprimatemodelsofparkinsonsdisease AT yihuiwu humanclinicalgradeparthenogeneticescderiveddopaminergicneuronsrecoverlocomotivedefectsofnonhumanprimatemodelsofparkinsonsdisease AT zhengxinliu humanclinicalgradeparthenogeneticescderiveddopaminergicneuronsrecoverlocomotivedefectsofnonhumanprimatemodelsofparkinsonsdisease AT lingminliang humanclinicalgradeparthenogeneticescderiveddopaminergicneuronsrecoverlocomotivedefectsofnonhumanprimatemodelsofparkinsonsdisease AT chaosheng humanclinicalgradeparthenogeneticescderiveddopaminergicneuronsrecoverlocomotivedefectsofnonhumanprimatemodelsofparkinsonsdisease AT jiehao humanclinicalgradeparthenogeneticescderiveddopaminergicneuronsrecoverlocomotivedefectsofnonhumanprimatemodelsofparkinsonsdisease AT liuwang humanclinicalgradeparthenogeneticescderiveddopaminergicneuronsrecoverlocomotivedefectsofnonhumanprimatemodelsofparkinsonsdisease AT weili humanclinicalgradeparthenogeneticescderiveddopaminergicneuronsrecoverlocomotivedefectsofnonhumanprimatemodelsofparkinsonsdisease AT qizhou humanclinicalgradeparthenogeneticescderiveddopaminergicneuronsrecoverlocomotivedefectsofnonhumanprimatemodelsofparkinsonsdisease AT baoyanghu humanclinicalgradeparthenogeneticescderiveddopaminergicneuronsrecoverlocomotivedefectsofnonhumanprimatemodelsofparkinsonsdisease |
_version_ |
1725223610180698112 |
spelling |
doaj-f77f4dbd823b467fa8caeb5efda5c8ce2020-11-25T00:57:33ZengElsevierStem Cell Reports2213-67112018-07-01111171182Human Clinical-Grade Parthenogenetic ESC-Derived Dopaminergic Neurons Recover Locomotive Defects of Nonhuman Primate Models of Parkinson's DiseaseYu-Kai Wang0Wan-Wan Zhu1Meng-Hua Wu2Yi-Hui Wu3Zheng-Xin Liu4Ling-Min Liang5Chao Sheng6Jie Hao7Liu Wang8Wei Li9Qi Zhou10Bao-Yang Hu11State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China; Beijing Stem Cell Bank, Chinese Academy of Sciences, Beijing 100190, ChinaState Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, ChinaState Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China; University of Chinese Academy of Sciences, Beijing 100049, ChinaState Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, ChinaState Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, ChinaState Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China; Beijing Stem Cell Bank, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing 100049, ChinaState Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, ChinaState Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China; Beijing Stem Cell Bank, Chinese Academy of Sciences, Beijing 100190, ChinaState Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China; Beijing Stem Cell Bank, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing 100049, ChinaState Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China; Beijing Stem Cell Bank, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing 100049, ChinaState Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China; Beijing Stem Cell Bank, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing 100049, China; Corresponding authorState Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China; Beijing Stem Cell Bank, Chinese Academy of Sciences, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing 100049, China; Corresponding authorSummary: Clinical application of stem cell derivatives requires clinical-grade cells and sufficient preclinical proof of safety and efficacy, preferably in primates. We previously successfully established a clinical-grade human parthenogenetic embryonic stem cell (hPESC) line, but the suitability of its subtype-specific progenies for therapy is not clear. Here, we compared the function of clinical-grade hPESC-derived midbrain dopaminergic (DA) neurons in two canonical protocols in a primate Parkinson's disease (PD) model. We found that the grafts did not form tumors and produced variable but apparent behavioral improvement for at least 24 months in most monkeys in both groups. In addition, a slight DA increase in the striatum correlates with significant functional improvement. These results demonstrated that clinical-grade hPESCs can serve as a reliable source of cells for PD treatment. Our proof-of-concept findings provide preclinical data for China's first ESC-based phase I/IIa clinical study of PD (ClinicalTrials.gov number NCT03119636). : Human ESCs are a potential source of regenerative medicine. However, safety and efficacy of ESC derivatives must be validated strictly before clinical application. Wang et al. manufactured clinical-grade human parthenogenetic ESC-derived DA neurons under CGMP conditions. The authors found that transplantation of these DA cells into monkeys was safe and provided preclinical data for human ESC-based clinical trials. Keywords: embryonic stem cell, Parkinson's disease, cell therapy, dopaminergic neuron, nonhuman primate, monkeyhttp://www.sciencedirect.com/science/article/pii/S2213671118302273 |